Harrison School of Pharmacy
Faculty and Staff Directory
Harrison School of Pharmacy
2316 Walker Building
Auburn, AL 36849
- B.S., Pharmacy - University of Wisconsin-Madison
- Ph.D., Social, Administrative and Clinical Pharmacy - University of Minnesota-Twin Cities
Dr. Richard Hansen was announced as Dean of the Harrison School of Pharmacy on Jan. 20, 2017, taking over the role on May 15. He is the sixth Dean in the history of HSOP and takes the position after serving as Gilliland Professor and head of HSOP's Department of Health Outcomes Research and Policy since 2010.
Since arriving at Auburn, Hansen has worked to improve the school’s national prominence among leading pharmacy schools. As head of the Department of Health Outcomes Research and Policy, he worked to inspire research by demonstrating that obtaining funding was achievable. Hansen has submitted grant or contract applications totaling more than $20 million and has published more than 50 original research articles in peer reviewed journals while at Auburn. Every faculty member in the department currently has active extramural research funding. During this time, the department also implemented a new curriculum in health outcomes research.
After earning a bachelor’s degree in pharmacy from the University of Wisconsin-Madison, Hansen practiced in both hospital and retail pharmacy settings. The work inspired him to return to graduate school and learn how to create more effective, efficient and safer health care systems. He received a doctorate from the Social, Administrative and Clinical Pharmacy graduate program at the University of Minnesota in 2003.
From 2003-10, Hansen was an assistant (2003-08) and associate (2008-10) professor in the Division of Pharmaceutical Outcomes and Policy at the University of North Carolina-Chapel Hill Eshelman School of Pharmacy.
Registered Pharmacist, Wisconsin Department of Safety & Professional Services
License Number: 12702-40
My work focuses on understanding and improving population-based health outcomes. I conduct studies in pharmacoepidemiology and health outcomes research to better understand how the benefits and harms of competing interventions or healthcare delivery models compare. My research also assesses factors influencing drug use, medication adherence, drug safety, and the effectiveness of practice-based interventions. The underlying goal of my research is to inform decision-making and policy through evaluation of healthcare interventions.
7/1/16 – 6/30/20
National Institutes of Health; Grant No. 2R01GM097618-04
Machine Learning for Adverse Drug Events
Subcontract PI (University of Wisconsin prime – Page)
$635,376 (Auburn subcontract)
9/30/15 – 9/29/20
U.S. Food and Drug Administration; Contract No. FDA BAA-13-0019
Comparative Surveillance of Generic Drugs by Machine Learning
Subcontract PI (Marshfield Clinic Research Foundation prime – Peissig)
$519,736 (Auburn subcontract)
9/15/15 – 8/31/18
U.S. Food and Drug Administration; Grant No. 1U01FD005486-01
Educating Groups Influencing Generic Drug Use
Co-Investigator (Qian PI)
9/10/14 – 9/9/16
U.S. Food and Drug Administration; Grant No. 1U01FD005272-02
Post-market Authorized Generic Evaluation (PAGE)
6/1/14 – 11/30/15
Agency for Healthcare Research and Quality; Grant No: 1R01HS023099-01
Continuity of Medication Management in Medicaid
Subcontract PI (UNC prime – Farley)
$65,244 (Auburn subcontract)
3/1/12 – 4/1/13
Auburn University Intramural Grants Program
SPIRIT – Storing Petabytes of Information for Research Into Tomorrow’s science
4/1/12 – 3/31/13
National Pharmaceutical Council
Heterogeneity of treatment effects across methods, populations, and data resources
6/1/11 – 6/30/12
Foundation for the National Institutes of Health
Observational Medical Outcomes Partnership; Grant No. HANSE11OMOP
Developing a structured process for measuring and interpreting health outcomes of interest in the OMOP common data model
1/1/06 – 1/31/13
North Carolina Division of Facilities Service
Medication Error Reporting in North Carolina Nursing Homes
Subcontract: Cecil G. Sheps Center for Health Services Research
Role: Subcontract PI
9/30/10 – 9/29/12
Agency for Healthcare Research and Quality; Grant No. 1R21HS019445
US Department of Health and Human Services
The Continuity of Medication Management (COMM) Study
Role: Subcontract PI
PYPC 7840 Pharmaceutical Economics, Outcomes, and Policy (Fall)
PYPC 7830 Pharmacoepidemiology (Spring)
PYPP 5970 Special Problems - Research Methods (Fall)
PYPC 7950/8950 Pharmacy Care Systems Graduate Seminar (Fall/Spring)
PYPC 5110 Law and Ethics (Spring)
Recent and Current Graduate Students:
Md Motiur Rahman (PhD student)
Ning Cheng (PhD student)
Yasser Alatawi (PhD student)
Saranrat Wittayanukorn (PhD 2015)
Kalyani Sonawane (PhD 2015)
Hansen RA, Voils CI, Farley JF, Powers BJ, Sanders LL, Sleath B, Maciejewski ML. Prescriber continuity and medication adherence for complex patients. Annals of Pharmacotherapy 2015; 49(3):293-302.
Sonawane K, Qian J, Hansen RA. Utilization patterns of antihypertensive drugs among the chronic kidney disease population in the US: A cross-sectional analysis of the National Health and Nutrition Examination Survey. Clinical Therapeutics 2015; 1(37):188-96.
Hansen RA, Zeng P, Ryan P, Gao J, Sonawane K, Teeter B, Westrich K, Dubois RW. Exploration of heterogeneity in distributed research network drug safety analyses. Research Synthesis Methods 2014; 5:352-370.
Mulherin DW, Hutchison AM, Thomas GJ, Hansen RA, Childress DT. Concordance of the SHEA-IDSA severity classification for Clotridium difficile infection and the ATLAS bedside scoring system in hospitalized adult patients. Infection 2014; 42(6):999-1005.
Desai RJ, Rao JK, Hansen RA, Fang G, Maciejewski M, Farley JF. Predictors of treatment initiation with tumor necrosis- inhibitors in patients with rheumatoid arthritis. Journal of Managed Care and Specialty Pharmacy 2014; 20(11):1110-20.
Desai RJ, Rao JK, Hansen RA, Fang G, Maciejewski M, Farley JF. TNF-alpha inhibitor treatment and risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study. Journal of Rheumatology 2014; 41(11):2129-36.
Nussbaumer B, Morgan LC, Reichenpfader U, Greenblatt A, Hansen RA, Van Noord M, Lux L, Gaynes BN, Gartlehner G. Comparative efficacy and risk of harms of immediate- vs. extended-release second generation antidepressants – a systematic review with network meta-analysis. CNS Drugs 2014; 28(8):699-712.
Gaynes BN, Lloyd SW, Lux L, Gartlehner G, Hansen RA, Brode S, Jonas D, Swinson-Evans, T, Viswanathan M, Lohr K. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis. Journal of Clinical Psychiatry 2014; 75(5):477-89.
Wittayanukorn S, Qian J, Hanasen RA. Prevalence of depressive symptoms and predictors of treatment among US adults from 2005 to 2010. General Hospital Psychiatry 2014; 36(3):330-6.
Maciejewski ML, Powers BJ, Sanders LL, Farley JF, Hansen RA, Sleath B, Voils CI. The intersection of patient complexity, prescriber continuity, and acute care utilization. Journal of General Internal Medicine 2014; 29(4):594-601.
Reichenpfader U, Gartlehner G, Greenblatt A, Morgan LC, Nussbaumer B, Hansen RA, Van Noord M, Lux L, Gaynes BN. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder – results from a systematic review with network meta-analysis. Drug Safety 2014; 37(1):19-31.
Hansen RA, Gray MD, Fox BI, Hollingsworth JC, Gao J, Hollingsworth ML, Carpenter DM. Expert panel assessment of acute liver injury identification in observational data. Research in Social and Administrative Pharmacy 2014; 10(1):156-67.
Watson LC, Esserman D, Ivey JL, Hansen RA, Lewis CL, Weinberger M, Roth MT. Enhancing Quality in Psychiatry Using Pharmacists (EQUIPP). American Journal of Geriatric Psychiatry 2014; 22(9):884-8.
Last Updated: February 21, 2020